Company intelligence / Profile preview

Brightmind.AI

Ownership: Private
Development stage: Preclinical

Overview

Brightmind.AI’s technology has demonstrated efficacy in reducing migraine attacks by over 50% for up to 90% of migraine sufferers according to research cited by the company. The first-generation professional-use device is approved for use; a large-scale randomized clinical trial is underway for the at-home version. Market launch and roll-out are planned with key clinic partnerships

Therapeutic areas: PsychiatryNeurology
Modalities: DeviceNon-pharmacological therapyTranscranial magnetic stimulation (TMS)
Industry: Therapeutic Medical Devices

Partnerships

Key clinic partnerships planned for market roll-outfunded by Seedfinancing – Deep Tech of BWAW/the BMK via awsbacked by VC Xista and FFG

Beyond the preview

Go deeper on Brightmind.AI.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Brightmind.AI.

Explore the full profile